Clinical Study Results, Stock Price Movements, and Acquisitions - Research Report on Gilead, Life Technologies, Jazz

  Clinical Study Results, Stock Price Movements, and Acquisitions - Research
 Report on Gilead, Life Technologies, Jazz Pharmaceuticals, CSI, and Smith &
                                    Nephew

Editor Note: For more information about this release, please scroll to bottom

PR Newswire

NEW YORK, December 11, 2013

NEW YORK, December 11, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Gilead
Sciences, Inc. (NASDAQ: GILD), Life Technologies Corp. (NASDAQ: LIFE), Jazz
Pharmaceuticals plc (NASDAQ: JAZZ), Cardiovascular Systems Inc. (NASDAQ:
CSII), and Smith & Nephew plc (ADR) (NYSE: SNN). Today's readers may access
these reports free of charge - including full price targets, industry analysis
and analyst ratings - via the links below.

Gilead Sciences, Inc. Research Report

On December 8, 2013, Gilead Sciences, Inc. (Gilead) announced the results of a
Phase 2 study (Study 101-09) evaluating idelalisib (an investigational oral
inhibitor of PI3K delta) for the treatment of patients with indolent
non-Hodgkin's lymphoma (iNHL), which is refractory (non-responsive) to
rituximab and to alkylating-agent-containing chemotherapy. Gilead informed
that in the study, single-agent treatment with idelalisib achieved an overall
response rate of 57% with a median duration of response of 12.5 months. Gilead
further informed that of the 71 patients who responded to therapy, seven (6%)
achieved a complete response, 63 (50%) had a partial response and one (1%) had
a minor response. Ajay Gopal, M.D., Associate Professor, University of
Washington School of Medicine and Associate Member, Clinical Research
Division, Fred Hutchinson Cancer Research Center in Seattle, Washington, said,
"It has been more than ten years since a treatment with a novel mechanism of
action has been approved for indolent NHL, underscoring the medical need for
new treatments for patients who are no longer responsive to currently
available therapies." Dr. Gopal added, "The overall response rate and
durability of response observed in this study suggest that idelalisib may
become a valuable new therapy for iNHL patients who have very limited
treatment options." The Full Research Report on Gilead Sciences, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/9898_GILD

--

Life Technologies Corp. Research Report

On December 6, 2013, Life Technologies Corp.'s (Life Technologies) stock rose
0.09%, ending the day at $75.69. Over the previous three trading sessions,
shares of Life Technologies gained 0.12% compared to the Nasdaq Composite
which gained 0.63% during the same period. The Full Research Report on Life
Technologies Corp. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/d5de_LIFE

--

Jazz Pharmaceuticals plc Research Report

On December 6, 2013, Jazz Pharmaceuticals plc's (Jazz Pharmaceuticals) stock
rose 2.36%, ending the day at $117.04. Over the previous three trading
sessions, shares of Jazz Pharmaceuticals gained 2.84% compared to the Nasdaq
Composite which gained 0.63% during the same period. The Full Research Report
on Jazz Pharmaceuticals plc - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/5fe3_JAZZ

--

Cardiovascular Systems Inc. Research Report

On December 3, 2013, Cardiovascular Systems Inc. (CSI) announced that the
Company's Diamondback 360 Coronary Orbital Atherectomy System (OAS) is being
used by physicians across the country to treat coronary artery disease. CSI
reported that this has followed the Company's recent PMA (premarket approval
application) approval from the US Food and Drug Administration (FDA) to market
the device as a treatment for severely calcified coronary arteries. David L.
Martin, CSI's President and CEO, said, "Significant arterial calcium is
present in nearly 40 percent of patients undergoing a percutaneous coronary
intervention, and contributes to poor outcomes and higher treatment costs in
coronary interventions when traditional therapies are used-including a
substantially higher occurrence of death and major adverse cardiac events."
Martin added, "Severe coronary arterial calcium is a vastly underestimated
problem in medicine, with limited treatment options. Our Diamondback 360
coronary system provides for initial therapeutic intervention for this complex
disease and we are excited about its growing use, as illustrated by the early
adoption and ongoing cases being performed at three U.S. hospitals by
prominent physicians. As we continue our controlled product rollout, we expect
to see this list of hospitals and prominent physicians expand nationally." The
Full Research Report on Cardiovascular Systems Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

http://www.analystscorner.com/r/full_research_report/11b9_CSII

--

Smith & Nephew plc (ADR) Research Report

On November 26, 2013, Smith & Nephew plc (ADR) (Smith & Nephew) announced that
it has agreed to acquire the assets and business of Politec Saúde relating to
Smith & Nephew's Advanced Wound Management products in Brazil. According to
the Company, the proposed acquisition promises approximately one quarter of
Politec's overall business. Smith & Nephew, however, did not disclose the
terms of the transaction. Olivier Bohuon, CEO of Smith & Nephew, added, "Being
closer to the customer is at the heart of our Emerging Markets strategy.
Brazil is an exciting long-term opportunity and this is an important
investment which creates a significant platform from which we can grow." The
Full Research Report on Smith & Nephew plc (ADR) - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

http://www.analystscorner.com/r/full_research_report/eed3_SNN

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

SOURCE Analysts' Corner

Contact: CONTACT PERSON: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North
America)
 
Press spacebar to pause and continue. Press esc to stop.